Akari Therapeutics, Plc EPS Ratio 2011-2025 | AKTX

EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.

The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares^[1]

EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.

A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.

EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.

Annual EPS Ratio Akari Therapeutics, Plc

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-0.09	-0.61	-0.74	-	-0.01	-0.01	-0.01	-0.03	-0.02	-0.05	-0.18	-0.17	-0.35	-0.18

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
-0.01	-0.74	-0.188

Quarterly EPS Ratio Akari Therapeutics, Plc

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.01	-	-	-	-	-	-	-	-0.01	-0.003	-	-0.06	-0.002	-0.002	-	-	-0.04	-0.04	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
-0.002	-0.06	-0.0209

References

Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.

EPS Ratio of other stocks in the Biotechnology industry

Issuer	EPS Ratio	Price	% 24h	Market Cap	Country
AC Immune SA ACIU	-0.97	$ 2.8	2.19 %	$ 229 M	Schweiz
ADiTx Therapeutics ADTX	-3.06 K	$ 2.49	-11.39 %	$ 32.8 K	USA
Aeterna Zentaris AEZS	-0.07	-	5.93 %	$ 314 M	Canada
Abeona Therapeutics ABEO	-2.53	$ 4.59	-4.08 %	$ 98.1 M	USA
ARCA biopharma ABIO	-3.87	-	1052.0 %	$ 415 M	USA
Applied Genetic Technologies Corporation AGTC	-0.36	-	-	$ 26.5 M	USA
Akouos AKUS	-2.52	-	0.23 %	$ 488 M	USA
Amneal Pharmaceuticals AMRX	-0.38	$ 12.12	-1.58 %	$ 3.74 B	USA
Axcella Health AXLA	-1.49	-	-16.42 %	$ 249 M	USA
Acer Therapeutics ACER	-1.66	-	2.71 %	$ 14 M	USA
Armata Pharmaceuticals ARMP	-1.91	$ 5.37	-20.68 %	$ 194 M	USA
Atreca BCEL	-2.52	-	-11.76 %	$ 5.79 M	USA
Brainstorm Cell Therapeutics BCLI	-2.31	-	-2.5 %	$ 5.88 M	USA
argenx SE ARGX	-7.99	$ 919.62	2.76 %	$ 25 B	Niderland
Ascendis Pharma A/S ASND	-8.28	$ 203.0	-3.72 %	$ 5 B	Danmark
Achieve Life Sciences ACHV	-1.5	$ 4.64	-0.32 %	$ 92 M	USA
BioDelivery Sciences International BDSI	0.85	-	-4.8 %	$ 255 M	USA
BeiGene, Ltd. BGNE	-0.47	-	0.49 %	$ 251 B	Cayman-islands
Acorda Therapeutics ACOR	-204	-	-24.86 %	$ 820 K	USA
Alterity Therapeutics Limited ATHE	-0.53	$ 3.36	2.73 %	$ 8.08 B	Australia
Acasti Pharma ACST	-0.79	-	4.01 %	$ 150 M	Canada
Bellerophon Therapeutics BLPH	-2.08	-	-74.18 %	$ 955 K	USA
BioLineRx Ltd. BLRX	-0.12	$ 3.29	-1.5 %	$ 908 M	Israel
BioMarin Pharmaceutical BMRN	2.25	$ 54.27	-1.38 %	$ 10.3 B	USA
Adaptimmune Therapeutics plc ADAP	-0.09	-	-15.15 %	$ 60.3 M	Britain
Baudax Bio BXRX	-177	-	0.59 %	$ 63 K	USA
AbbVie ABBV	-0.02	$ 224.99	-0.01 %	$ 398 B	USA
Cara Therapeutics CARA	-2.19	-	-3.03 %	$ 260 M	USA
CymaBay Therapeutics CBAY	-0.99	-	-	$ 3.45 B	USA
ChemoCentryx CCXI	-1.89	-	-	$ 3.74 B	USA
BioNTech SE BNTX	42.2	$ 96.22	-1.21 %	$ 27.2 B	Germany
Codiak BioSciences CDAK	-1.7	-	-55.98 %	$ 2.15 M	USA
Adaptive Biotechnologies Corporation ADPT	-1.08	$ 18.75	-0.48 %	$ 2.76 B	USA
Avid Bioservices CDMO	-2.23	-	-	$ 789 M	USA
BioXcel Therapeutics BTAI	-23.5	$ 1.92	-7.01 %	$ 4.87 M	USA
Biogen BIIB	11.2	$ 179.76	1.11 %	$ 26.2 B	USA
Cerevel Therapeutics Holdings CERE	-2.67	-	-	$ 7.29 B	USA
ContraFect Corporation CFRX	-125	-	-5.16 %	$ 5.39 M	USA
Beam Therapeutics BEAM	-4.58	$ 23.52	-2.22 %	$ 1.94 B	USA
AbCellera Biologics ABCL	-0.55	$ 3.45	-0.72 %	$ 1.02 B	Canada
Cabaletta Bio CABA	-1.65	$ 2.37	-2.67 %	$ 2.77 M	USA
Clearside Biomedical CLSD	-0.53	-	-	$ 25.3 M	USA
Celsion Corporation CLSN	-1.62	-	-6.63 %	$ 13.9 M	USA
Clovis Oncology CLVS	-2.29	-	-7.23 %	$ 13 M	USA
Advaxis ADXS	-7.99	-	-9.65 %	$ 45.9 M	USA
Checkmate Pharmaceuticals CMPI	-2.84	-	-	$ 231 M	USA
Chimerix CMRX	-0.93	-	-	$ 756 M	USA
Concert Pharmaceuticals CNCE	-2.33	-	-	$ 401 M	USA